newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and